• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用分子模拟方法研究新型 2-氨基吡啶衍生物作为有效和选择性 c-Met 激酶型 1 抑制剂的结合模式。

Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches.

机构信息

School of Pharmacy, Lanzhou University, 199 West Donggang Rd., Lanzhou 730013, China.

出版信息

Molecules. 2020 Dec 24;26(1):52. doi: 10.3390/molecules26010052.

DOI:10.3390/molecules26010052
PMID:33374386
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7795969/
Abstract

The mesenchymal epithelial cell transforming factor c-Met, encoded by c-Met proto-oncogene and known as a high-affinity receptor for Hepatocyte Growth Factor (HGF), is one of the receptor tyrosine kinases (RTKs) members. The HGF/c-Met signaling pathway has close correlation with tumor growth, invasion and metastasis. Thus, c-Met kinase has emerged as a prominent therapeutic target for cancer drug discovery. Recently a series of novel 2-aminopyridine derivatives targeting c-Met kinase with high biological activity were reported. In this study, 3D quantitative structure-activity relationship (QSAR), molecular docking and molecular dynamics simulations (MD) were employed to research the binding modes of these inhibitors.The results show that both the atom-based and docking-based CoMFA (Q = 0.596, R = 0.950 in atom-based model and Q = 0.563, R = 0.985 in docking-based model) and CoMSIA (Q = 0.646, R = 0.931 in atom-based model and Q = 0.568, R = 0.983 in docking-based model) models own satisfactory performance with good reliabilities and powerful external predictabilities. Molecular docking study suggests that Tyr1230 and Arg1208 might be the key residues, and electrostatic and hydrogen bond interactions were shown to be vital to the activity, concordance with QSAR analysis. Then MD simulation was performed to further explore the binding mode of the most potent inhibitor. The obtained results provide important references for further rational design of c-Met Kinase type I inhibitors.

摘要

间质上皮细胞转化因子 c-Met,由 c-Met 原癌基因编码,被称为肝细胞生长因子(HGF)的高亲和力受体,是受体酪氨酸激酶(RTKs)家族的成员之一。HGF/c-Met 信号通路与肿瘤的生长、侵袭和转移密切相关。因此,c-Met 激酶已成为癌症药物发现的重要治疗靶点。最近,一系列针对 c-Met 激酶具有高生物活性的新型 2-氨基吡啶衍生物被报道。在本研究中,采用 3D 定量构效关系(QSAR)、分子对接和分子动力学模拟(MD)研究了这些抑制剂的结合模式。结果表明,基于原子和基于对接的 CoMFA(基于原子模型的 Q = 0.596,R = 0.950 和基于对接模型的 Q = 0.563,R = 0.985)和 CoMSIA(基于原子模型的 Q = 0.646,R = 0.931 和基于对接模型的 Q = 0.568,R = 0.983)模型都具有良好的性能,具有良好的可靠性和强大的外部预测能力。分子对接研究表明,Tyr1230 和 Arg1208 可能是关键残基,静电和氢键相互作用对活性至关重要,与 QSAR 分析一致。然后进行 MD 模拟进一步探索最有效的抑制剂的结合模式。获得的结果为进一步合理设计 c-Met 激酶 I 型抑制剂提供了重要参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/baf51d0e5dab/molecules-26-00052-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/0544a969d55c/molecules-26-00052-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/f8cc8141de57/molecules-26-00052-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/dd0cb80a2ea2/molecules-26-00052-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/7221d7b4dc23/molecules-26-00052-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/3b9a02407599/molecules-26-00052-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/f5f16b9fad7f/molecules-26-00052-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/a1febac5cbb3/molecules-26-00052-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/1d05cf153ab6/molecules-26-00052-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/6e8000c3720a/molecules-26-00052-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/5075cc5571e3/molecules-26-00052-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/faf3c0c67283/molecules-26-00052-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/174defb6297b/molecules-26-00052-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/baf51d0e5dab/molecules-26-00052-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/0544a969d55c/molecules-26-00052-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/f8cc8141de57/molecules-26-00052-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/dd0cb80a2ea2/molecules-26-00052-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/7221d7b4dc23/molecules-26-00052-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/3b9a02407599/molecules-26-00052-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/f5f16b9fad7f/molecules-26-00052-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/a1febac5cbb3/molecules-26-00052-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/1d05cf153ab6/molecules-26-00052-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/6e8000c3720a/molecules-26-00052-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/5075cc5571e3/molecules-26-00052-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/faf3c0c67283/molecules-26-00052-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/174defb6297b/molecules-26-00052-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12f/7795969/baf51d0e5dab/molecules-26-00052-g013.jpg

相似文献

1
Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches.采用分子模拟方法研究新型 2-氨基吡啶衍生物作为有效和选择性 c-Met 激酶型 1 抑制剂的结合模式。
Molecules. 2020 Dec 24;26(1):52. doi: 10.3390/molecules26010052.
2
3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation.基于分子动力学模拟和结合自由能计算的高活性 c-Met 抑制剂的 3D-QSAR 辅助设计。
J Biomol Struct Dyn. 2019 May;37(8):2165-2178. doi: 10.1080/07391102.2018.1479309. Epub 2018 Nov 1.
3
In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.基于 3D-QSAR、分子对接和分子动力学模拟,设计新型(5-咪唑-2-基-4-苯基嘧啶-2-基)[2-(2-吡啶基氨基)乙基]胺衍生物作为糖原合酶激酶 3 的抑制剂。
Comput Biol Chem. 2020 Oct;88:107328. doi: 10.1016/j.compbiolchem.2020.107328. Epub 2020 Jul 4.
4
Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach.使用对接、基于结构的3D-QSAR和分子动力学模拟对一系列布鲁顿酪氨酸激酶(Btk)抑制剂进行分子建模研究:一种联合方法。
Arch Pharm Res. 2016 Mar;39(3):328-39. doi: 10.1007/s12272-015-0698-0. Epub 2015 Dec 23.
5
Computational Simulation Study of Potential Inhibition of c-Met Kinase Receptor by Phenoxy pyridine Derivatives: Based on QSAR, Molecular Docking, Molecular Dynamics.基于 QSAR、分子对接、分子动力学的对甲氧基吡啶衍生物抑制 c-Met 激酶受体的计算模拟研究
Chem Biodivers. 2024 Oct;21(10):e202400782. doi: 10.1002/cbdv.202400782. Epub 2024 Aug 30.
6
Design of Novel Chemotherapeutic Agents Targeting Checkpoint Kinase 1 Using 3D-QSAR Modeling and Molecular Docking Methods.使用3D-QSAR建模和分子对接方法设计靶向检查点激酶1的新型化疗药物
Curr Comput Aided Drug Des. 2016;12(4):302-313. doi: 10.2174/1573409912666160901112720.
7
Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.嘌呤衍生物作为新型 CDK2 抑制剂的分子建模与设计研究。
Molecules. 2018 Nov 9;23(11):2924. doi: 10.3390/molecules23112924.
8
Integrated molecular docking, 3D QSAR and molecular dynamics simulation studies on indole derivatives for designing new Pim-1 inhibitors.基于吲哚衍生物的整合分子对接、3D QSAR和分子动力学模拟研究以设计新型Pim-1抑制剂
J Recept Signal Transduct Res. 2020 Feb;40(1):1-14. doi: 10.1080/10799893.2020.1713809. Epub 2020 Jan 13.
9
Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.具有潜在 c-Met 激酶抑制活性的新型抗肿瘤 1,2,4-三嗪类化合物的设计、合成及分子模拟研究。
Bioorg Chem. 2018 Feb;76:154-165. doi: 10.1016/j.bioorg.2017.11.006. Epub 2017 Nov 16.
10
Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies.计算机模拟研究咪唑并[2,1-b]恶唑衍生物作为潜在的突变 BRAF 激酶抑制剂:3D-QSAR、分子对接、分子动力学模拟和 ADMETox 研究。
J Biomol Struct Dyn. 2024 Jul;42(10):5268-5287. doi: 10.1080/07391102.2023.2233629. Epub 2023 Jul 9.

引用本文的文献

1
The Structure-Antiproliferative Activity Relationship of Pyridine Derivatives.吡啶衍生物的结构-抗增殖活性关系。
Int J Mol Sci. 2024 Jul 11;25(14):7640. doi: 10.3390/ijms25147640.

本文引用的文献

1
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.克唑替尼治疗伴有 ALK 重排和 c-Met 过表达的晚期非小细胞肺癌。
BMC Cancer. 2018 Nov 26;18(1):1171. doi: 10.1186/s12885-018-5078-y.
2
Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.新型奥拉帕尼类似物的合成、初步生物学评价及作为多功能 PARP-1 和胆碱酯酶抑制剂的分子对接研究。
J Enzyme Inhib Med Chem. 2019 Dec;34(1):150-162. doi: 10.1080/14756366.2018.1530224.
3
Receptor Tyrosine Kinase-Targeted Cancer Therapy.
受体酪氨酸激酶靶向癌症治疗。
Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491.
4
Computational study of the binding mechanism between farnesoid X receptor α and antagonist N-benzyl-N-(3-(tertbutyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) benzamide.法尼醇 X 受体 α 与拮抗剂 N-苄基-N-(3-(叔丁基)-4-羟基苯基)-2,6-二氯-4-(二甲基氨基)苯甲酰胺之间结合机制的计算研究。
J Biomol Struct Dyn. 2019 Apr;37(6):1628-1640. doi: 10.1080/07391102.2018.1462735. Epub 2018 May 2.
5
Molecular dynamics simulation and binding free energy studies of novel leads belonging to the benzofuran class inhibitors of Mycobacterium tuberculosis Polyketide Synthase 13.新型苯并呋喃类结核分枝杆菌聚酮合酶 13 抑制剂的分子动力学模拟及结合自由能研究。
J Biomol Struct Dyn. 2019 Apr;37(6):1616-1627. doi: 10.1080/07391102.2018.1462734. Epub 2018 May 4.
6
Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.通过分子动力学模拟和结合自由能计算研究洛拉替尼与 c-ros 原癌基因 1(ROS1)受体酪氨酸激酶的结合机制。
J Biomol Struct Dyn. 2018 Sep;36(12):3106-3113. doi: 10.1080/07391102.2017.1378127. Epub 2017 Sep 25.
7
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.发现(R)-6-(1-(8-氟-6-(1-甲基-1H-吡唑-4-基)-[1,2,4]三唑并[4,3-a]吡啶-3-基)乙基)-3-(2-甲氧基乙氧基)-1,6-萘啶-5(6H)-酮(AMG 337),一种具有高游离靶标覆盖率和强大体内抗肿瘤活性的强效和选择性 MET 抑制剂。
J Med Chem. 2016 Mar 24;59(6):2328-42. doi: 10.1021/acs.jmedchem.5b01716. Epub 2016 Feb 11.
8
The Origin of Layer Structure Artifacts in Simulations of Liquid Water.液态水模拟中层状结构伪像的起源
J Chem Theory Comput. 2006 Jan;2(1):1-11. doi: 10.1021/ct0502256.
9
ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB.ff14SB:提高源自ff99SB的蛋白质侧链和主链参数的准确性。
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713. doi: 10.1021/acs.jctc.5b00255. Epub 2015 Jul 23.
10
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.阿尔替拉替尼通过平衡抑制MET、TIE2和VEGFR2来抑制肿瘤生长、侵袭、血管生成以及微环境介导的耐药性。
Mol Cancer Ther. 2015 Sep;14(9):2023-34. doi: 10.1158/1535-7163.MCT-14-1105. Epub 2015 Aug 18.